Want to see JP:3183 full AI Analyst Report?
Top Page
WIN-Partners Co., Ltd.
(3183)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥1,431.00
▲(7.92% Upside)
Action:Upgraded
Date:08/17/26
The score is led by solid financial performance—especially the very low leverage and steady revenue growth—tempered by uneven cash-flow history and modest margin erosion. Technical indicators are neutral-to-soft (negative MACD; neutral RSI), while valuation is supportive due to a reasonable P/E and a strong dividend yield.
Positive Factors
Balance sheet strength
Extremely low leverage and sizable equity give WIN-Partners durable financial flexibility. Minimal debt reduces interest burden and supports capital allocation for dividends, investments in distribution, or absorbing shocks, enabling resilience across business cycles.
Negative Factors
Cash-flow volatility
Free cash flow swings and prior negative FCF indicate working-capital or timing sensitivity. Volatile cash conversion reduces predictability of funds for dividends, investment or M&A, and can force reliance on reserves despite reported earnings strength.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low leverage and sizable equity give WIN-Partners durable financial flexibility. Minimal debt reduces interest burden and supports capital allocation for dividends, investments in distribution, or absorbing shocks, enabling resilience across business cycles.
Read all positive factors
WIN-Partners Co., Ltd. (3183) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥36.72B
Dividend Yield4.23%
Average Volume (3M)11.73K
Price to Earnings (P/E)17.3
Beta (1Y)0.65
Revenue Growth9.99%
EPS Growth0.17%
CountryJP
Employees653
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)73.67
Shares Outstanding30,503,310
10 Day Avg. Volume13,600
30 Day Avg. Volume11,726
Financial Highlights & Ratios
PEG Ratio2.30
Price to Book (P/B)1.64
Price to Sales (P/S)0.42
P/FCF Ratio14.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
WIN-Partners Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1973 and headquartered in Tokyo, Japan, WIN-Partners Co., Ltd. leverages its subsidiaries to distribute a comprehensive range of medical devices to healthcare institutions, primarily across Japan. Its diverse product offerings inclu...
How the Company Makes Money
null...
WIN-Partners Co., Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.28B | 90.39B | 81.41B | 77.06B | 70.85B | 66.39B |
| Gross Profit | 10.73B | 10.66B | 9.89B | 9.53B | 8.66B | 8.52B |
| EBITDA | 3.25B | 3.32B | 3.10B | 2.92B | 3.11B | 2.82B |
| Net Income | 2.04B | 2.12B | 2.02B | 1.84B | 2.05B | 1.83B |
Balance Sheet | ||||||
| Total Assets | 49.63B | 50.63B | 46.65B | 47.75B | 43.91B | 41.59B |
| Cash, Cash Equivalents and Short-Term Investments | 15.00B | 15.93B | 16.21B | 18.16B | 16.77B | 15.57B |
| Total Debt | 784.33M | 713.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 27.43B | 27.34B | 22.58B | 24.37B | 21.12B | 19.86B |
| Stockholders Equity | 22.20B | 23.29B | 24.07B | 23.39B | 22.78B | 21.72B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.70B | 1.59B | 2.54B | -525.17M | -136.90M |
| Operating Cash Flow | 0.00 | 2.93B | 2.06B | 3.04B | 445.15M | 2.62B |
| Investing Cash Flow | 0.00 | -132.31M | -2.17B | -219.47M | 1.92B | -2.89B |
| Financing Cash Flow | 0.00 | -3.08B | -1.83B | -1.45B | -1.16B | -1.28B |
WIN-Partners Co., Ltd. Technical Analysis
Negative
1326.00
Price Trends
1277.04
Negative
1264.79
Positive
1285.73
Negative
Market Momentum
-1.36
Positive
47.49
Neutral
51.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3183, the sentiment is Negative. The current price of 1326 is above the 20-day moving average (MA) of 1285.70, above the 50-day MA of 1277.04, and above the 200-day MA of 1285.73, indicating a bearish trend. The MACD of -1.36 indicates Positive momentum. The RSI at 47.49 is Neutral, neither overbought nor oversold. The STOCH value of 51.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3183.
WIN-Partners Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥36.72B | 17.32 | ― | 3.97% | 9.99% | 0.17% | |
64 Neutral | ¥41.88B | 12.83 | ― | 0.91% | 6.17% | -33.01% | |
59 Neutral | ¥89.66B | 44.98 | 6.35% | ― | 24.03% | 34.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥21.41B | -98.57 | ― | 3.12% | -6.64% | 67.08% | |
46 Neutral | ¥4.11B | 12.24 | ― | 1.41% | 14.91% | -39.00% |
* Healthcare Sector Average
JP:3183
WIN-Partners Co., Ltd.
1,273.00
-11.18
-0.87%
JP:4480
Medley
2,687.00
203.00
8.17%
JP:7061
Japan Hospice Holdings Inc.
484.00
-797.94
-62.24%
JP:7071
Amvis Holdings.Inc.
412.00
-193.99
-32.01%
JP:7600
Japan Medical Dynamic Marketing, Inc.
807.00
298.39
58.67%
WIN-Partners Co., Ltd. Corporate Events
WIN-Partners Posts Q1 Profit Decline But Sticks to Growth and Dividend Plans
Aug 4, 2026
WIN-Partners Co., Ltd. reported consolidated net sales of ¥23,970 million for the three months ended June 30, 2026, an 8.5% year-on-year increase, while operating profit fell 15.0% to ¥596 million and profit attributable to owners of par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.